This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2018 Feb;19(2):157-159.

doi: 10.1016/S1470-2045(18)30007-X. Epub 2018 Jan 18.

Revisiting RECIST: the case of treatment beyond progression

Affiliations

PMID: 29361472
DOI: 10.1016/S1470-2045(18)30007-X

Comment

Revisiting RECIST: the case of treatment beyond progression

Adil I Daud. Lancet Oncol. 2018 Feb.

. 2018 Feb;19(2):157-159.

doi: 10.1016/S1470-2045(18)30007-X. Epub 2018 Jan 18.

Author

Affiliation

¹ University of California, San Francisco, CA 94113, USA. Electronic address: adil.daud@ucsf.edu.

PMID: 29361472
DOI: 10.1016/S1470-2045(18)30007-X

No abstract available

PubMed Disclaimer

Comment on

Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis.
Beaver JA, Hazarika M, Mulkey F, Mushti S, Chen H, He K, Sridhara R, Goldberg KB, Chuk MK, Chi DC, Chang J, Barone A, Balasubramaniam S, Blumenthal GM, Keegan P, Pazdur R, Theoret MR. Beaver JA, et al. Lancet Oncol. 2018 Feb;19(2):229-239. doi: 10.1016/S1470-2045(17)30846-X. Epub 2018 Jan 18. Lancet Oncol. 2018. PMID: 29361469 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations